- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07629479
Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH (EP-BTUEP)
Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Benign prostatic hyperplasia is a common cause of lower urinary tract symptoms in aging men. Surgical treatment is indicated when medical therapy fails or when symptoms remain bothersome. Bipolar transurethral enucleation of the prostate is an established endoscopic surgical technique for benign prostatic obstruction, but standard endoscopic prostate surgery may be associated with loss of antegrade ejaculation.
This study will evaluate whether an ejaculation-preserving modification of bipolar transurethral enucleation of the prostate can preserve ejaculatory function while maintaining effective relief of lower urinary tract symptoms. The ejaculation-preserving technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum. The control group will undergo standard bipolar transurethral enucleation of the prostate.
Eligible sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment will be randomized in a 1:1 ratio to ejaculation-preserving B-TUEP or standard B-TUEP. Sexual and urinary outcomes will be assessed using validated questionnaires and objective urinary parameters. Follow-up assessments will include ejaculatory function, erectile function, International Prostate Symptom Score, post-void residual urine, uroflowmetry, perioperative complications, and need for retreatment.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Hany F Badawy, MD
- Numéro de téléphone: +201149525028
- E-mail: HANYFATHY86@GMAIL.COM
Lieux d'étude
-
-
Beni Suweif Governorate
-
Banī Suwayf, Beni Suweif Governorate, Egypte
- Recrutement
- Department of Urology- Beni-Suef University Hospitals
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.
- Sexually active patients with a continuous relationship with the same partner.
- International Prostate Symptom Score of 8 or greater.
- Transrectal ultrasound-estimated prostate size between 40 and 100 cc.
- Eligible for bipolar transurethral enucleation of the prostate.
- Ability to complete the required sexual and urinary function questionnaires.
- Ability to provide written informed consent.
Exclusion Criteria:
- Preoperative sexual dysfunction.
- Preoperative ejaculatory dysfunction.
- Diagnosis or suspicion of prostate cancer.
- Neurological disorders affecting lower urinary tract or sexual function.
- Detrusor hypocontractility.
- Catheter-dependent patients.
- Patients with bladder stones.
- Inability or refusal to provide informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ejaculation-Preserving B-TUEP
Participants assigned to this arm will undergo ejaculation-preserving bipolar transurethral enucleation of the prostate.
The technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
Ejaculation-preserving bipolar transurethral enucleation of the prostate will be performed with preservation of the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
|
Comparateur actif: Standard B-TUEP
Participants assigned to this arm will undergo standard bipolar transurethral enucleation of the prostate without the ejaculation-preserving modifications used in the experimental arm.
|
Standard bipolar transurethral enucleation of the prostate will be performed according to the conventional surgical technique without preservation of the paracollicular tissue and the area approximately 1 cm proximal to the verumontanum.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Function Score From Baseline to 6 Months
Délai: Baseline and 6 months postoperatively
|
Ejaculatory function will be assessed using the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form function score.
The function score is based on three ejaculatory function items assessing ejaculation frequency, ejaculation force, and ejaculation volume.
The total function score ranges from 1 to 15, with higher scores indicating better ejaculatory function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
A smaller decrease or a positive change indicates better preservation of ejaculatory function.
|
Baseline and 6 months postoperatively
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Bother Score at 6 Months
Délai: 6 months postoperatively
|
Ejaculatory bother will be assessed using the bother item of the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form.
The bother score ranges from 0 to 5, with higher scores indicating greater bother related to ejaculatory dysfunction.
|
6 months postoperatively
|
|
Preservation of Antegrade Ejaculation at 6 Months
Délai: 6 months postoperatively
|
The proportion of participants with preserved antegrade ejaculation at 6 months after surgery will be compared between the ejaculation-preserving B-TUEP group and the standard B-TUEP group.
Preserved antegrade ejaculation will be defined as patient-reported antegrade seminal emission during orgasm after resumption of sexual activity.
Participants reporting absent ejaculation, dry ejaculation, or retrograde ejaculation will be considered not to have preserved antegrade ejaculation.
|
6 months postoperatively
|
|
Change in International Index of Erectile Function-5 Score From Baseline to 6 Months
Délai: Baseline and 6 months postoperatively
|
Erectile function will be assessed using the International Index of Erectile Function-5 questionnaire.
The total score ranges from 5 to 25, with higher scores indicating better erectile function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in International Prostate Symptom Score From Baseline to 6 Months
Délai: Baseline and 6 months postoperatively
|
Lower urinary tract symptoms will be assessed using the International Prostate Symptom Score.
The total score ranges from 0 to 35, with higher scores indicating more severe urinary symptoms.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in Maximum Urinary Flow Rate From Baseline to 6 Months
Délai: Baseline and 6 months postoperatively
|
Maximum urinary flow rate will be measured by uroflowmetry and reported in milliliters per second.
The outcome will be calculated as the 6-month postoperative maximum urinary flow rate minus the baseline maximum urinary flow rate.
|
Baseline and 6 months postoperatively
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Hany F Badawy, MD, Faculty of medicine Beni-Suef University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FMBSUREC07092025EjBTUEP
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .